DOCSLIB.ORG

Newborndxtm Advanced Sequencing Evaluation Disorders List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Newborndxtm Advanced Sequencing Evaluation Disorders List NewbornDxTM Advanced Sequencing Evaluation Disorders List Skeletal Abnormal bone and cartilage Contractures (cont.) Disorder Associated gene(s) Disorder Associated gene(s) Alpha-mannosidosis MAN2B1 Lethal arthrogryposis, with anterior GLE1 horn cell disease Camurati-Engelmann disease TGFB1 Lethal congenital contracture syndrome ADCY6, CNTNAP1, DNM2, Cerebrocostomandibular syndrome SNRPB ERBB3, GLE1, MYBPC1, Chondrocalcinosis ANKH PIP5K1C Chondrodysplasia punctata ARSE, EBP, PTH1R Marden-Walker syndrome PIEZO2 Chondrodysplasia with joint dislocations IMPAD1 Multicentric osteolysis, MMP2 nodulosis, and arthropathy Craniometaphyseal dysplasia ANKH Osteogenesis Imperfecta BMP1 Eiken syndrome PTH1R Osteogenesis imperfecta COL1A1, COL1A2, CRTAP, Familial osteochondritis dissecans ACAN FKBP10, IFITM5, P3H1, PPIB, Fibrodysplasia ossificans progressiva ACVR1 SERPINF1, SERPINH1, SP7, TMEM38B, WNT1 Hyperphosphatasia with PGAP3, PIGV mental retardation syndrome Osteopathia striata with cranial sclerosis AMER1 Kabuki syndrome KDM6A Osteopetrosis with renal tubular acidosis CA2 Keutel syndrome MGP Van den Ende-Gupta syndrome SCARF2 Klippel-Feil syndrome GDF3, GDF6, MEOX1, Winchester syndrome MMP14 MYO18B Lethal restrictive dermopathy ZMPSTE24 Hand and foot abnormalities Mandibuloacral dysplasia with ZMPSTE24 Adams-Oliver syndrome ARHGAP31, DOCK6, EOGT, type B lipodystrophy NOTCH1 Marshall-Smith syndrome NFIX Atelosteogenesis SLC26A2 Metaphyseal chondrodysplasia PTH1R Bardet-Biedl syndrome ARL6, BBIP1, IFT27, LZTFL1, MKKS, MKS1 Multiple epiphyseal dysplasia with EIF2AK3 early-onset diabetes mellitus Brachydactyly BMP2, BMPR1B, HOXD13, Short-rib thoracic dysplasia DYNC2H1, IFT140, IFT80, NEK1, PTHLH TTC21B, WDR19, WDR35 Catel-Manzke syndrome TGDS Sotos syndrome NFIX, NSD1 Ciliopathy CC2D2A, CEP290, IFT172, SDCCAG8 Bone fragility COACH syndrome CC2D2A, TMEM67 Glycogen storage disease type IV GBE1 Coffin-Siris syndrome ARID1A, ARID1B, SMARCA4, Arthrogryposis-renal dysfunction-cholestasis VIPAS39, VPS33B SMARCB1, SMARCE1 syndrome Congenital clubfoot with or without deficiency PITX1 Arthrogryposis, mental retardation, and seizures SLC35A3 of long bones, mirror-image polydactyly Bruck syndrome PLOD2 Culler-Jones syndrome GLI2 Caffey disease COL1A1 Diastrophic dysplasia SLC26A2 Cerebrooculofacioskeletal syndrome ERCC1, ERCC5 Hay-Wells syndrome TP63 Cockayne syndrome ERCC6, ERCC6, ERCC8 Joubert syndrome CC2D2A, CEP290, CEP41, NPHP1, NPHP4 Congenital contractural arachnodactyly FBN2 Loeys-Dietz syndrome SMAD3, TGFB2, TGFB3, TGF- Congenital contractures, hypotonia, NALCN BR1, TGFBR2 and developmental delay Meckel syndrome B9D1, CEP290, EXOC4, NPHP3, TMEM67 Contractures Megalencephaly-capillary syndrome PIK3CA Distal arthrogryposis ECEL1, MYBPC1, MYH3, TNNI2, TNNT3, TPM2 Multiple synostoses syndrome NOG Ehlers-Danlos syndrome B4GALT7, CHST14, COL1A1, Opsismodysplasia INPPL1 COL1A2, COL3A1, COL5A1, Pallister-Hall syndrome GLI3 COL5A2, FKBP14, PLOD1 Pitt-Hopkins-like syndrome CNTNAP2 Histiocytosislymphadenopathy plus syndrome SLC29A3 Postaxial polydactyly ZNF141 Infantile hypotonia, psychomotor NALCN retardation, characteristic facies This document lists disorders and genes included in the NewbornDxTM Advanced Sequencing Evaluation Panel as of November 2019. Athena Diagnostics offers a comprehensive genetic test menu. Customers in the US and Canada, please call 1.800.394.4493 (toll-free), or visit us online at AthenaDiagnostics.com/NewbornDx. Hand and foot abnormalities (cont.) Short stature (cont.) Disorder Associated gene(s) Disorder Associated gene(s) Rubinstein-Taybi syndrome EP300 Marshall syndrome COL11A1 Scalp-ear-nipple syndrome KCTD1 Meier-Gorlin syndrome CDC6, CDT1, ORC1, ORC4, ORC6 Split-hand/foot malformation DLX5, FBXW4 Microcephalic osteodysplastic PCNT Split-hand/foot malformation with DLX5 primordial dwarfism sensorineural hearing loss Microcephaly, short stature, and polymicro- RTTN Syndactyly GJA1 gyria with seizures Synpolydactyly FBLN1, HOXD13 Multiple joint dislocation syndrome B3GAT3 Temtamy preaxial CHSY1 Nicolaides-Baraitser syndrome SMARCA2 brachydactyly syndrome Nijmegen breakage syndrome NBN Townes-Brocks syndrome SALL1 Noonan syndrome A2ML1, BRAF, KRAS, LZTR1, Trichorhinophalangeal syndrome TRPS1 NRAS, PTPN11, RAF1, RASA2, Trismus-pseudocamptodactyly syndrome MYH8 RIT1, RRAS, SOS1, SOS2 Weill-Marchesani syndrome ADAMTS10 Noonan syndrome-like disorder with or CBL without juvenile myelomonocytic leukemia Overgrowth Noonan-like syndrome with SHOC2 loose anagen hair Beckwith-Wiedemann syndrome CDKN1C Osteoarthritis with mild chondrodysplasia COL2A1 Kosaki overgrowth syndrome PDGFRB Phosphorylase kinase PHKB Perlman syndrome DIS3L2 deficiency of liver and muscle Sotos syndrome NFIX, NSD1 Platyspondylic lethal skeletal dysplasia COL2A1 Resistance to insulin-like growth factor I IGF1R Short stature Rhizomelic chondrodysplasia punctata AGPS, GNPAT 17-alpha-hydroxylasedeficient CYP17A1 Roberts syndrome ESCO2 congenital adrenal hyperplasia Rothmund-Thomson syndrome RECQL4 3-M syndrome CCDC8, CUL7, OBSL1 SC phocomelia syndrome ESCO2 Aarskog-Scott syndrome FGD1 Schimke immunoosseous dysplasia SMARCAL1 Achondrogenesis COL2A1, SLC26A2, TRIP11 Schwartz-Jampel syndrome HSPG2 Achondroplasia FGFR3 Short stature with nonspecific NPR2 Acrocapitofemoral dysplasia IHH skeletal abnormalities Acrodysostosis with or PDE4D Short stature, onychodysplasia, facial POC1A without hormone resistance dysmorphism, and hypotrichosis Acromesomelic chondrodysplasia GDF5 Smith-McCort dysplasia DYM, RAB33B Acromesomelic dysplasia BMPR1B Spondylo-megaepiphysealmetaphyseal NKX3-2 Anauxetic dysplasia POP1 dysplasia Auriculocondylar syndrome GNAI3, PLCB4 Spondylocheirodysplasia SLC39A13 Brachydactyly BMP2, BMPR1B, HOXD13, Spondylocostal dysostosis DLL3, HES7, MESP2, TBX6 PTHLH Spondyloenchondrodysplasia ACP5 Cardiofaciocutaneous BRAF, KRAS, MAP2K1 with immune dysregulation syndrome Spondyloepimetaphyseal dysplasia MMP13 Carney complex MYH8, PRKAR1A Spondyloepimetaphyseal KIF22 Coffin-Lowry syndrome RPS6KA3 dysplasia with joint laxity Costello syndrome HRAS Spondyloepiphyseal dysplasia with CHST3 congenital joint dislocations COUSIN syndrome TBX15 Spondylometaepiphyseal dysplasia DDR2 Dyggve-Melchior-Clausen DYM disease Spondyloperipheral dysplasia COL2A1 Ellis-van Creveld syndrome EVC, EVC2 Stickler syndrome COL11A1, COL2A1, COL9A1 Epiphyseal chondrodysplasia NPR2 Thanatophoric dysplasia FGFR3 Fibrochondrogenesis COL11A1 Weyers acrofacial dysostosis EVC, EVC2 Floating-Harbor syndrome SRCAP Wiedemann-Steiner syndrome KMT2A Geleophysic dysplasia ADAMTSL2 Skull abnormalities Intrahepatic cholestasis of pregnancy ABCB11 3MC syndrome MASP1 KBG syndrome ANKRD11 Apert syndrome FGFR2 Kniest dysplasia COL2A1 Beare-Stevenson syndrome FGFR2 This document lists disorders and genes included in the NewbornDxTM Advanced Sequencing Evaluation Panel as of November 2019. Athena Diagnostics offers a comprehensive genetic test menu. Customers in the US and Canada, please call 1.800.394.4493 (toll-free), or visit us online at AthenaDiagnostics.com/NewbornDx. Skull abnormalities (cont.) Upper and/or lower limb defects (cont.) Disorder Associated gene(s) Disorder Associated gene(s) Bent bone dysplasia syndrome FGFR2 Omodysplasia GPC6 Carpenter syndrome MEGF8, RAB23 Otospondylomegaepiphyseal COL11A2 dysplasia Cleidocranial dysplasia RUNX2 Paget disease of bone TNFRSF11B Cranioectodermal dysplasia IFT122, IFT43, WDR35 Peters plus syndrome B3GLCT Cranioosteoarthropathy HPGD Raine syndrome FAM20C Craniosynostosis ERF, TCF12 Robinow syndrome ROR2, WNT5A Crouzon syndrome FGFR2 Schneckenbecken dysplasia SLC35D1 Frank-ter Haar syndrome SH3PXD2B Skeletal disease LMBR1 Hydrolethalus syndrome HYLS1 Small patella syndrome TBX4 Knobloch syndrome COL18A1 Spondylocarpotarsal synostosis FLNB Lenz-Majewski hyperostotic dwarfism PTDSS1 syndrome Oculodentodigital dysplasia GJA1 Stuve-Wiedemann syndrome/ LIFR Pycnodysostosis CTSK Schwartz-Jampel syndrome Ritscher-Schinzel syndrome CCDC22, KIAA0196 Temtamy syndrome C12orf57 Saethre-Chotzen syndrome FGFR2, TWIST1 Ulnar-mammary syndrome TBX3 Schinzel-Giedion midface retraction syndrome SETBP1 Weissenbacher-Zweymuller syndrome COL11A2 Shprintzen-Goldberg syndrome SKI Respiratory Tall stature Abnormal breathing Marfan syndrome FBN1 Brown-Vialetto-Van Laere syndrome SLC52A2, SLC52A3 Weaver syndrome EZH2 Central hypoventilation syndrome ASCL1, EDN3, GDNF, PHOX2B, RET Upper and/or lower limb defects Hyperekplexia SLC6A5 Acro-renal-ocular syndrome SALL4 Neonatal diabetes with cerebellar PTF1A Acrofacial dysostosis SF3B4 agenesis Bainbridge-Ropers syndrome ASXL3 Pitt-Hopkins syndrome NRXN1, TCF4 Campomelic dysplasia SOX9 Pitt-Hopkins-like syndrome CNTNAP2 Cartilage-hair hypoplasiaanauxetic dysplasia RMRP spectrum disorders Chronic respiratory infection/disease Caudal regression syndrome VANGL1 Alpha-1-antitrypsin deficiency SERPINA1 Chondrodysplasia punctata ARSE, EBP, PTH1R Cystic fibrosis CFTR Desbuquois dysplasia CANT1, XYLT1 Keutel syndrome MGP Duane-radial ray syndrome SALL4 Developmental abnormalities Eiken syndrome PTH1R Hereditary hemorrhagic telangiectasia ACVRL1, ENG Endocrinecerebroosteodysplasia ICK Primary pulmonary arterial hypertension BMPR2, CAV1, KCNK3, SMAD9 Frontometaphyseal dysplasia FLNA Pulmonary venoocclusive disease EIF2AK4 Fuhrmann syndrome WNT7A Greenberg skeletal dysplasia LBR Pulmonary fibrosis Holt-Oram syndrome SALL4, TBX5 Hermansky-Pudlak syndrome AP3B1, BLOC1S6 Hypophosphatasia ALPL Dyskeratosis congenita DKC1, RTEL1, TERT, TINF2
Load more

Recommended publications
  • The Diversity of Dolichol-Linked Precursors to Asn-Linked Glycans Likely Results from Secondary Loss of Sets of Glycosyltransferases
    The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases John Samuelson*†, Sulagna Banerjee*, Paula Magnelli*, Jike Cui*, Daniel J. Kelleher‡, Reid Gilmore‡, and Phillips W. Robbins* *Department of Molecular and Cell Biology, Boston University Goldman School of Dental Medicine, 715 Albany Street, Boston, MA 02118-2932; and ‡Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School, Worcester, MA 01665-0103 Contributed by Phillips W. Robbins, December 17, 2004 The vast majority of eukaryotes (fungi, plants, animals, slime mold, to N-glycans of improperly folded proteins, which are retained in and euglena) synthesize Asn-linked glycans (Alg) by means of a the ER by conserved glucose-binding lectins (calnexin͞calreticulin) lipid-linked precursor dolichol-PP-GlcNAc2Man9Glc3. Knowledge of (13). Although the Alg glycosyltransferases in the lumen of ER this pathway is important because defects in the glycosyltrans- appear to be eukaryote-specific, archaea and Campylobacter sp. ferases (Alg1–Alg12 and others not yet identified), which make glycosylate the sequon Asn and͞or contain glycosyltransferases dolichol-PP-glycans, lead to numerous congenital disorders of with domains like those of Alg1, Alg2, Alg7, and STT3 (1, 14–16). glycosylation. Here we used bioinformatic and experimental Protists, unicellular eukaryotes, suggest three notable exceptions methods to characterize Alg glycosyltransferases and dolichol- to the N-linked glycosylation path described in yeast and animals PP-glycans of diverse protists, including many human patho- (17). First, the kinetoplastid Trypanosoma cruzi (cause of Chagas gens, with the following major conclusions. First, it is demon- myocarditis), fails to glucosylate the dolichol-PP-linked precursor strated that common ancestry is a useful method of predicting and so makes dolichol-PP-GlcNAc2Man9 (18).
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • Physical Interactions Between the Alg1, Alg2, and Alg11 Mannosyltransferases of the Endoplasmic Reticulum
    Glycobiology vol. 14 no. 6 pp. 559±570, 2004 DOI: 10.1093/glycob/cwh072 Advance Access publication on March 24, 2004 Physical interactions between the Alg1, Alg2, and Alg11 mannosyltransferases of the endoplasmic reticulum Xiao-Dong Gao2, Akiko Nishikawa1, and Neta Dean1 begins on the cytosolic face of the ER, where seven sugars (two N-acetylglucoseamines and five mannoses) are added 1Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York, Stony Brook, sequentially to dolichyl phosphate on the outer leaflet of NY 11794-5215, and 2Research Center for Glycoscience, National the ER, using nucleotide sugar donors (Abeijon and Institute of Advanced Industrial Science and Technology, Tsukuba Hirschberg, 1992; Perez and Hirschberg, 1986; Snider and Downloaded from https://academic.oup.com/glycob/article/14/6/559/638968 by guest on 30 September 2021 Central 6, 1-1 Higashi, Tsukuba 305-8566, Japan Rogers, 1984). After a ``flipping'' or translocation step, the Received on January 26, 2004; revised on March 2, 2004; accepted on last seven sugars (four mannoses and three glucoses) are March 2, 2004 added within the lumen of the ER, using dolichol-linked sugar donors (Burda and Aebi, 1999). Once assembled, the The early steps of N-linked glycosylation involve the synthesis oligosaccharide is transferred from the lipid to nascent of a lipid-linked oligosaccharide, Glc3Man9GlcNAc2-PP- protein in a reaction catalyzed by oligosaccharyltransferase. dolichol, on the endoplasmic reticulum (ER) membrane. After removal of terminal glucoses and a single mannose, Prior to its lumenal translocation and transfer to nascent nascent glycoproteins bearing the N-linked Man8GlcNAc2 glycoproteins, mannosylation of Man5GlcNAc2-PP-dolichol core can exit the ER to the Golgi, where this core may is catalyzed by the Alg1, Alg2, and Alg11 mannosyltrans- undergo further carbohydrate modifications.
    [Show full text]
  • Podocyte Specific Knockdown of Klf15 in Podocin-Cre Klf15flox/Flox Mice Was Confirmed
    SUPPLEMENTARY FIGURE LEGENDS Supplementary Figure 1: Podocyte specific knockdown of Klf15 in Podocin-Cre Klf15flox/flox mice was confirmed. (A) Primary glomerular epithelial cells (PGECs) were isolated from 12-week old Podocin-Cre Klf15flox/flox and Podocin-Cre Klf15+/+ mice and cultured at 37°C for 1 week. Real-time PCR was performed for Nephrin, Podocin, Synaptopodin, and Wt1 mRNA expression (n=6, ***p<0.001, Mann-Whitney test). (B) Real- time PCR was performed for Klf15 mRNA expression (n=6, *p<0.05, Mann-Whitney test). (C) Protein was also extracted and western blot analysis for Klf15 was performed. The representative blot of three independent experiments is shown in the top panel. The bottom panel shows the quantification of Klf15 by densitometry (n=3, *p<0.05, Mann-Whitney test). (D) Immunofluorescence staining for Klf15 and Wt1 was performed in 12-week old Podocin-Cre Klf15flox/flox and Podocin-Cre Klf15+/+ mice. Representative images from four mice in each group are shown in the left panel (X 20). Arrows show colocalization of Klf15 and Wt1. Arrowheads show a lack of colocalization. Asterisk demonstrates nonspecific Wt1 staining. “R” represents autofluorescence from RBCs. In the right panel, a total of 30 glomeruli were selected in each mouse and quantification of Klf15 staining in the podocytes was determined by the ratio of Klf15+ and Wt1+ cells to Wt1+ cells (n=6 mice, **p<0.01, unpaired t test). Supplementary Figure 2: LPS treated Podocin-Cre Klf15flox/flox mice exhibit a lack of recovery in proteinaceous casts and tubular dilatation after DEX administration.
    [Show full text]
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original Articles
    Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original articles Beckwith-Wiedemann syndrome: a demonstration of the mechanisms responsible for the excess J Med Genet: first published as on 1 April 1992. Downloaded from of transmitting females C Moutou, C Junien, / Henry, C Bonai-Pellig 217 Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome D Viljoen, R Ramesar 221 Sex reversal in a child with a 46,X,Yp+ karyotype: support for the existence of a gene(s), located in distal Xp, involved in testis formation T Ogata, J R Hawkins, A Taylor, N Matsuo, J-1 Hata, P N Goodfellow 226 Highly polymorphic Xbol RFLPs of the human 21 -hydroxylase genes among Chinese L Chen, X Pan, Y Shen, Z Chen, Y Zhang, R Chen 231 Screening of microdeletions of chromosome 20 in patients with Alagille syndrome C Desmaze, J F Deleuze, A M Dutrillaux, G Thomas, M Hadchouel, A Aurias 233 Confirmation of genetic linkage between atopic IgE responses and chromosome 1 1 ql 3 R P Young, P A Sharp, J R Lynch, J A Faux, G M Lathrop, W 0 C M Cookson, J M Hopkini 236 Age at onset and life table risks in genetic counselling for Huntington's disease P S Harper, R G Newcombe 239 Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1) E Coto, S Aguado, J Alvarez, M J Menendez-DIas, C Lopez-Larrea 243 Short communication Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene S E Pound, A D Carothers, P M Pignatelli, A M Macnicol, M L Watson, A F Wright 247 Technical note A strategy for the rapid isolation of new PCR based DNA polymorphisms P R Hoban, M F Santibanez-Koref, J Heighway 249 http://jmg.bmj.com/ Case reports Campomelic dysplasia associated with a de novo 2q;1 7q reciprocal translocation I D Young, J M Zuccollo, E L Maltby, N J Broderick 251 A complex chromosome rearrangement with 10 breakpoints: tentative assignment of the locus for Williams syndrome to 4q33-q35.1 R Tupler, P Maraschio, A Gerardo, R Mainieri G Lanzi L Tiepolo 253 on September 26, 2021 by guest.
    [Show full text]
  • The Endocytic Membrane Trafficking Pathway Plays a Major Role
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Liverpool Repository RESEARCH ARTICLE The Endocytic Membrane Trafficking Pathway Plays a Major Role in the Risk of Parkinson’s Disease Sara Bandres-Ciga, PhD,1,2 Sara Saez-Atienzar, PhD,3 Luis Bonet-Ponce, PhD,4 Kimberley Billingsley, MSc,1,5,6 Dan Vitale, MSc,7 Cornelis Blauwendraat, PhD,1 Jesse Raphael Gibbs, PhD,7 Lasse Pihlstrøm, MD, PhD,8 Ziv Gan-Or, MD, PhD,9,10 The International Parkinson’s Disease Genomics Consortium (IPDGC), Mark R. Cookson, PhD,4 Mike A. Nalls, PhD,1,11 and Andrew B. Singleton, PhD1* 1Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 2Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain 3Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 4Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 5Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom 6Department of Pathophysiology, University of Tartu, Tartu, Estonia 7Computational Biology Group, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA 8Department of Neurology, Oslo University Hospital, Oslo, Norway 9Department of Neurology and Neurosurgery, Department of Human Genetics, McGill University, Montréal, Quebec, Canada 10Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada 11Data Tecnica International, Glen Echo, Maryland, USA ABSTRACT studies, summary-data based Mendelian randomization Background: PD is a complex polygenic disorder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Advances in Understanding the Genetics of Syndromes Involving Congenital Upper Limb Anomalies
    Review Article Page 1 of 10 Advances in understanding the genetics of syndromes involving congenital upper limb anomalies Liying Sun1#, Yingzhao Huang2,3,4#, Sen Zhao2,3,4, Wenyao Zhong1, Mao Lin2,3,4, Yang Guo1, Yuehan Yin1, Nan Wu2,3,4, Zhihong Wu2,3,5, Wen Tian1 1Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China; 2Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing 100730, China; 3Medical Research Center of Orthopedics, Chinese Academy of Medical Sciences, Beijing 100730, China; 4Department of Orthopedic Surgery, 5Department of Central Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China Contributions: (I) Conception and design: W Tian, N Wu, Z Wu, S Zhong; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Y Huang; (V) Data analysis and interpretation: L Sun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Wen Tian. Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China. Email: [email protected]. Abstract: Congenital upper limb anomalies (CULA) are a common birth defect and a significant portion of complicated syndromic anomalies have upper limb involvement. Mostly the mortality of babies with CULA can be attributed to associated anomalies. The cause of the majority of syndromic CULA was unknown until recently. Advances in genetic and genomic technologies have unraveled the genetic basis of many syndromes- associated CULA, while at the same time highlighting the extreme heterogeneity in CULA genetics. Discoveries regarding biological pathways and syndromic CULA provide insights into the limb development and bring a better understanding of the pathogenesis of CULA.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]